Volume 100, Issue 6 pp. 1045-1050
EDITORIAL

Is FFR dead? A conversation in cardiology

Morton J. Kern MD

Corresponding Author

Morton J. Kern MD

Long Beach Healthcare Center, Charlotte, North Carolina, USA

Correspondence Morton J. Kern, MD, MSCAI, FACC, FAHA, Long Beach Veteran's Administration Medical Center, 5901 East 7th St, 111C, Long Beach, CA 90822, USA. 

Email: [email protected]

Search for more papers by this author
David Cox MD

David Cox MD

Long Beach Healthcare Center, Charlotte, North Carolina, USA

Search for more papers by this author
William Fearon MD

William Fearon MD

Stanford University, Palo Alto, California, USA

Search for more papers by this author
Nils Johnson MD

Nils Johnson MD

University of Houston, Houston, Texas, USA

Search for more papers by this author
Lloyd Klein MD

Lloyd Klein MD

University of California SF, Sonoma, California, USA

Search for more papers by this author
Mitch Krucoff MD

Mitch Krucoff MD

Duke University, Raleigh, North Carolina, USA

Search for more papers by this author
Jeffery Moses MD

Jeffery Moses MD

Columbia University, New York City, New York, USA

Search for more papers by this author
Srihari S. Naidu MD

Srihari S. Naidu MD

Westchester Medical Center, Westchester, New York, USA

Search for more papers by this author
Duane Pinto MD

Duane Pinto MD

Harvard University, Boston, Massachusetts, USA

Search for more papers by this author
Steve Ramee MD

Steve Ramee MD

Ochsner Clinic, New Orleans, Louisiana, USA

Search for more papers by this author
Paul Teirstein MD

Paul Teirstein MD

Scripps Clinic, La Jolla, California, USA

Search for more papers by this author
Alan Yeung MD

Alan Yeung MD

Stanford University, Palo Alto, California, USA

Search for more papers by this author
First published: 23 October 2022
First page image

CONFLICTS OF INTEREST

Dr. Kern is a speaker for Abbott Vascular, Acist Medical Inc, Boston Scientific, Opsens Inc, Philips Inc. Dr. Fearon has research support from Abbott, Boston, Edwards, and Medtronic; consulting agreements with CathWorks and Siemens and equity options with HeartFlow. Dr. Johnson has received significant institutional research support from Philips Volcano Corporation (DEFINE-FLOW, NCT02328820); has an institutional licensing agreement with Boston Scientific for the smart-minimum FFR algorithm commercialized under 510(k) K191008; and has pending patents on diagnostic methods for quantifying aortic stenosis and TAVI physiology and on algorithms to correct pressure tracings from fluid-filled catheters. Dr. Moses has equity in Covanos. Dr. Pinto is a speaker for Abbott Vascular, Boston Scientific Inc. Dr. Teirstein Is a speaker for Acist Medical. Dr. Yeung is on the scientific board of Boston Scientific and Medtronic. The remaining authors declare no conflict of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.